Barclays Initiates Coverage of DexCom with Overweight Rating
Fintel reports that on October 7, 2026, Barclays initiated coverage of DexCom (NASDAQGS:DXCM) (WBAG:DXCM) with a Overweight recommendation.
This initiation follows a prior action by Barclays on May 18, 2026, when the firm maintained an Underweight rating on the stock. DexCom, Inc., based in the United States, operates within the healthcare sector, specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems. Other recent analyst actions include RBC Capital maintaining an Outperform rating on October 1, 2026. Additionally, TD Cowen reiterated a Buy rating and Truist Securities maintained a Buy rating on September 18, 2026.
Prior to the rating action, DexCom's common stock closed at $83.39 on October 6, 2026. The stock has experienced a price change of -3.75% over a one-week period, relative to a baseline close of $86.64 on September 29, 2026. Over a one-month period, the stock recorded a price change of -5.13% from a baseline close of $87.90 on September 4, 2026.
As of October 2, 2026, the current consensus target mean for DexCom is $96.73, with a median target of $96.90. This mean target represents an implied change of +16.00% from the stock's valuation. The prior consensus target mean was $95.75 as of September 15, 2026, reflecting a consensus target revision of +1.02%.
The aggregate analyst recommendation profile for the period beginning September 1, 2026, consists of 36 total recommendations, with 15 strong buy, 16 buy, 5 hold, 0 sell, and 0 strong sell ratings. This distribution reflects 86.1% positive, 13.9% hold, and 0.0% negative recommendations, which remains unchanged from the prior recommendation period starting August 1, 2026.
In its latest earnings report on July 30, 2026, DexCom reported an actual EPS of 0.7, compared to an estimate of 0.6229, representing an EPS surprise of +12.38%. The company's actual revenue was $1,308,400,000.00, compared to an estimated revenue of $1,316,031,070.00. The company's upcoming earnings date is scheduled for October 22, 2026. Additionally, a Form 8-K filing submitted to the Securities and Exchange Commission on September 10, 2026, disclosed under Item 5.02 the departure of directors or certain officers; election of directors.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Overweight | initiated coverage | |
| October 1, 2026 | RBC Capital | Outperform | Outperform | maintained |
| September 18, 2026 | TD Cowen | Buy | Buy | reiterated |
| September 18, 2026 | Truist Securities | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.